idarubicinol

Subscribe to Selected New Research on idarubicinol

19 relevant articles (1 outcomes, 5 trials/studies) found for this Bio-Agent

Description: RN given refers to (7S-(7alpha,9alpha,9(R*))-isomer

Also Known As:

13-dihydroidarubicin; 4-demethoxy-14-hydroxydaunorubicin; idarubicinol, (7S-(7alpha,9alpha,9(S*)))-isomer

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fioravanti, A: 1 article (12/2005)
2.	Di Paolo, A: 1 article (12/2005)
3.	Orlandi, P: 1 article (12/2005)
4.	Danesi, R: 1 article (12/2005)
5.	Barbara, C: 1 article (12/2005)
6.	Del Tacca, M: 1 article (12/2005)
7.	Bocci, G: 1 article (12/2005)
8.	Kasimir-Bauer, S: 1 article (02/2000)
9.	Schröder, J K: 1 article (02/2000)
10.	Scheulen, M E: 1 article (02/2000)

Related Diseases

1.	Leukemia 01/01/1995 - "The anthracycline analog idarubicin (ID) is useful in the treatment of leukemias, and is of further interest because of the unique activity of its major circulating metabolite idarubicinol (IDOL)" 12/01/1994 - "We investigated the antileukemic potency of idarubicinol (IDAol), a 13-dihydro (13-OH) metabolite of idarubicin (IDA), on the HL60 line of human leukemia cells" 10/15/1990 - "Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report." 04/01/2000 - "We measured the DNA-binding of idarubicin and idarubicinol and the induced apoptosis in the human promyelocytic HL-60 leukemia cell line" 01/01/1996 - "Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 08/01/1999 - "The concentration of idarubicinol in the marginal zone between brain and tumor tissue was lower than in central tumor tissue, but was still higher than the plasma concentration in 2 of the 3 examined cases" 08/01/1999 - "The median tumor:concurrent plasma ratio of idarubicinol was 5.7 (range 1.7-18)" 12/01/2005 - "Despite extensive preclinical evaluation in several experimental models, no studies have determined the effect of idarubicin and its metabolite idarubicinol on multicellular spheroids, a model which mimics the microregions of solid tumors" 08/01/1999 - "The concentrations of idarubicin and of idarubicinol in tumor tissue exceeded the concurrent plasma concentrations as well as the peak plasma concentrations in all cases" 03/24/1989 - "A method is given for the determination of idarubicin and its main metabolite, idarubicinol, in plasma from cancer patients" Get all the results and reference details, order at left...
3.	Breast Neoplasms (Breast Cancer) 12/01/2005 - "The principal aim of the present study was to investigate the in vitro cytotoxicity of idarubicin and its metabolite idarubicinol on MCF-7 breast cancer cells growing as monolayers or multicellular spheroids and to evaluate the influence of the length of exposure on the cytotoxic effect of both drugs" 12/01/2005 - "Idarubicin and idarubicinol effects on breast cancer multicellular spheroids." 06/01/1989 - "The pharmacokinetics of orally administered idarubicin (22.5 mg/m2/week) and idarubicinol were studied for 12 weeks in 14 patients with breast cancer" 08/01/1999 - "The uptake of idarubicin and its major metabolite idarubicinol in brain tumor tissue were measured in a patient with a brain metastasis from breast cancer and in 4 patients with malignant glioma after an oral dose of idarubicin (45 mg/m2 in 1 patient; 25 mg/m2 in 4 patients), given 15-24 h before brain tumor resection" Get all the results and reference details, order at left...
4.	Lymphoma (Lymphomas) 10/01/2001 - "To clarify the pharmacokinetic properties of idarubicin (IDA) in Japanese patients and to clarify the relationship between the pharmacokinetic parameters of IDA or idarubicinol (IDAol), an active metabolite of IDA, and leukocytopenia or neutropenia, we examined the pharmacokinetics of IDA in patients with malignant lymphoma" 02/01/2000 - "We treated 16 patients with poor prognosis lymphoma in a phase I-II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors" Get all the results and reference details, order at left...
5.	DNA Damage 01/01/1992 - "Idarubicin was more potent than the other three anthracycline analogs and idarubicinol was much more effective than the other alcohol metabolites in inducing DNA damage" 06/01/1991 - "In contrast, the concentrations of idarubicin and idarubicinol needed to produce 50% growth inhibition (0.005 and 0.006 microM, respectively) were about 20 times lower than drug levels that induced significant DNA damage" 01/01/1992 - "These studies in human leukemia and human glioblastoma cell lines support the hypothesis that idarubicinol plays an important role in the antitumor activity of idarubicin and that the activities of idarubicin and idarubicinol are related to their ability to damage DNA." Get all the results and reference details, order at left...
15 Diseases and 19 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Idarubicin (4 Demethoxydaunorubicin)
2.	Anthracyclines
3.	Melphalan (Alkeran)
4.	Multidrug Resistance-Associated Proteins
5.	P-Glycoprotein
6.	Cyclosporine (Ciclosporin)
7.	Epirubicin (Ellence)
8.	Vinblastine (Vinblastine Sulfate)
9.	Doxorubicin (Adriamycin)
10.	DNA (Deoxyribonucleic Acid)
13 Drugs and Important Bio-Agents and 17 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>